Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

Organovo Holdings, Inc. announced that it has successfully advanced the use of its first inflammatory bowel disease model and has achieved the next milestone, target validation.